Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
Has Arcutis Biotherapeutics, Inc. (ARQT) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Arcutis Biotherapeutics, Inc. is one of 1025 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Arcutis Biotherapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for ARQT's full-year earnings has moved 35.7% higher. This is a sign of impro
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255GlobeNewswire
- Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic DermatitisGlobeNewswire
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
- Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely [Seeking Alpha]Seeking Alpha
ARQT
Earnings
- 8/14/24 - Beat
ARQT
Sec Filings
- 9/5/24 - Form 4
- 9/3/24 - Form 144
- 8/21/24 - Form 4
- ARQT's page on the SEC website